Trulieve Cannabis (NYSE:TRLV) Stock Price Up 8.3% – Still a Buy?

Posted by George Bondi on Aug 15th, 2026

Trulieve Cannabis Corp. (NYSE:TRLV – Get Free Report)’s stock price shot up 8.3% during trading on Thursday . The company traded as high as $9.74 and last traded at $9.8650. 663,856 shares traded hands during mid-day trading, an increase of 3% from the average session volume of 647,423 shares. The stock had previously closed at $9.11.

Wall Street Analyst Weigh In

Several research firms have issued reports on TRLV. Weiss Ratings started coverage on shares of Trulieve Cannabis in a research report on Tuesday, June 16th. They set a “sell (d-)” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $15.00 price objective on shares of Trulieve Cannabis in a report on Friday, August 7th. Wall Street Zen lowered Trulieve Cannabis from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Zacks Research raised Trulieve Cannabis to a “hold” rating in a research note on Thursday, June 18th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Trulieve Cannabis has an average rating of “Hold” and a consensus price target of $15.00.

Get Our Latest Report on TRLV

Trulieve Cannabis Trading Down 0.1%

The company has a fifty day moving average of $8.93.

Trulieve Cannabis (NYSE:TRLV – Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.05. The firm had revenue of $271.00 million for the quarter, compared to analysts’ expectations of $268.82 million. As a group, equities analysts forecast that Trulieve Cannabis Corp. will post -1.01 earnings per share for the current fiscal year.

Insider Activity at Trulieve Cannabis

In other news, CEO Kim A. Rivers sold 400,000 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $8.17, for a total transaction of $3,268,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,913,724 shares of the company’s stock, valued at approximately $15,635,125.08. This represents a 17.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,699,007 shares of company stock worth $14,661,355 over the last ninety days. Corporate insiders own 3.79% of the company’s stock.

Trulieve Cannabis Company Profile

(Get Free Report)

Trulieve Cannabis Corp. is a vertically integrated cannabis company focused on the cultivation, processing, and retail sale of medical and adult-use cannabis products. The company offers a range of products that may include flower, pre-rolls, concentrates, edibles, vape products, and topicals through its dispensary network and branded product portfolio.

Trulieve’s operations have been centered primarily in the United States, with a strong presence in Florida and additional markets in other states where cannabis is legally regulated.